Drugs & Aging

, Volume 18, Issue 8, pp 607–620 | Cite as

Age-Related Changes in Wound Healing

Review Article

Abstract

Evidence for age-related effects on wound healing have been derived for the most part from empirical observations without adjustment for confounders other than age. Age-related changes in the structure and function of the skin do occur. Some of these changes result from chronic solar radiation exposure rather than chronological age per se. The tensile strength of wounds, accumulation of wound healing factors and rate of wound closure have all been examined in relation to chronological aging. However, the clinical impact of these changes in acute wound healing appears to be small. Poor healing in chronic wounds is more often related to comorbid conditions rather than age alone. Since the majority of these chronic wounds occur in elderly populations, this has contributed to the conclusion that aging itself may influence healing.

Progress in understanding the role that growth factors play in wound healing and the ability to synthesise adequate quantities of these factors for clinical use has led to clinical trials evaluating their use in wound healing. The results of these studies, with the possible exception of those in diabetic wounds, have been disappointing. Insight into the wound healing process indicates that growth factors interact during wound healing in a sequential and orderly process. Improved wound healing may require different clinical designs or the use of these factors in a precisely timed sequential administration.

References

  1. 1.
    Goodson WH, Hunt TK. Wound healing and aging. J Investigative Dermatology 1979; 73: 88–91CrossRefGoogle Scholar
  2. 2.
    Strigini L, Ryan T. Wound healing in elderly human skin. Clin Dermatol 1996; 14: 197–206PubMedCrossRefGoogle Scholar
  3. 3.
    Albina JE. Nutrition and wound healing. JPEN J Parenter Enteral Nutr 1994; 18: 367–76PubMedCrossRefGoogle Scholar
  4. 4.
    Holt DR, Kirk SJ, Regan MC, et al. Effect of age on wound healing in healthy human beings. Surgery 1992; 112: 293–8PubMedGoogle Scholar
  5. 5.
    Gniadecka M, Jemec GB. Quantitative evaluation of chronological ageing and photoageing in vivo: studies on skin echogenicity and thickness. Br J Dermatol 1998; 139(5): 815–21PubMedCrossRefGoogle Scholar
  6. 6.
    Panyakhamlerd K, Chotnopparatpattara P, Taechakraichana N, et al. Skin thickness in different menopausal status. J Med Assoc Thailand 1999; 82: 352–6Google Scholar
  7. 7.
    Lavker RM. Structural alterations in exposed and unexposed aged skin. J Invest Dermatol 1979; 73: 59–66PubMedCrossRefGoogle Scholar
  8. 8.
    Kurban R, Bhawan J. Histological changes in skin associated with aging. J Dermatol Surg Oncol 1990; 16: 908–14PubMedGoogle Scholar
  9. 9.
    Montagna W, Carlisle K. Structural changes in aging human skin. J Invest Dermatol 1979; 73: 47–53PubMedCrossRefGoogle Scholar
  10. 10.
    Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 1979; 73: 141–3PubMedCrossRefGoogle Scholar
  11. 11.
    Ashcroft GS, Kielty CM, Horan MA, et al. Age-related changes in the temporal and spatial distributions of fibrillin and elastin mRNAs and proteins in acute cutaneous wounds of healthy humans. J Pathol 1997; 183: 80–9PubMedCrossRefGoogle Scholar
  12. 12.
    Gilchrest B, Stoff J, Soter N. Chronological aging alters the response to ultraviolet-induced inflammation in human skin. J Invest Dermatol 1992; 79: 11–15CrossRefGoogle Scholar
  13. 13.
    Kelly RI, Pearse R, Bull RH, et al. The effects of aging on the cutaneous microvasculature. J Am Acad Dermatol 1995; 33: 749–56PubMedCrossRefGoogle Scholar
  14. 14.
    Pienta KJ, Coppey DS. Characterization of the subtypes of cell motility in ageing human skin fibroblasts. Mech Ageing Devel 1990; 56: 99–105CrossRefGoogle Scholar
  15. 15.
    Kondo H, Nomaguchi TA, Yonezawa Y. Effects of serum from human subjects of different ages on migration in vitro of human fibroblasts. Mech Ageing Devel 1989; 47: 25–37CrossRefGoogle Scholar
  16. 16.
    Rattan SIS, Derventzi A. Altered cellular responsiveness during ageing. BioEssays 1991; 13: 601–6PubMedCrossRefGoogle Scholar
  17. 17.
    Katz MH, Kirsner RS, Eaglstein WH, et al. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 1991; 25: 1054–8PubMedCrossRefGoogle Scholar
  18. 18.
    Heldin C, Westermark B. Role of platelet-derived growth factor in vivo. In: Clark RAF, editor. The molecular and cellular biology of wound repair. 2nd ed. New York (NY): Plenum Press, 1996: 249–74Google Scholar
  19. 19.
    Deuel TF, Senior RM, Chang D, et al. Platelet factor 4 is a chemotaxtic factor for neutrophils and monocytes. Proc Natl Acad Sci 1981; 74: 4584–7CrossRefGoogle Scholar
  20. 20.
    Schultz G, Rotatari DS, Clark W. EGF and TGFα in wound healing and repair. J Cell Biochem 1991; 45: 346–52PubMedCrossRefGoogle Scholar
  21. 21.
    Sporn MB, Roberts AB. Transforming growth factor beta: recent progress and new challenges. J Cell Biol 1992; 119: 1017–21PubMedCrossRefGoogle Scholar
  22. 22.
    Hanahan DJ. Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 1986; 55: 483–509PubMedCrossRefGoogle Scholar
  23. 23.
    Ming WJ, Bersani L, Mantovani A. Tumour necrosis factor is chemotactic for monocytes and polymophonuclear leukocytes. J Immunol 1987; 138: 469–74Google Scholar
  24. 24.
    Pierce GF, Mustoe TA, Lingelbach J, et al. Platelet derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanism. J Cellular Biology 1989; 109: 429–40CrossRefGoogle Scholar
  25. 25.
    Shimokado K, Raines EW, Madles DK, et al. A significant part of macrophages derives growth factor consists of 2 forms of PDGF. Cell 1985; 43: 277–86PubMedCrossRefGoogle Scholar
  26. 26.
    Madtes DK, Raines EW, Sakariassen KS, et al. Induction of transforming growth factor alpha in activated human alveolar macrophages. Cell 1988; 53: 285–93PubMedCrossRefGoogle Scholar
  27. 27.
    Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type beta TGF, by activated human macrophages. Proc Natl Acad Sci USA 1987; 84: 6020–4PubMedCrossRefGoogle Scholar
  28. 28.
    Baird A, Mormede P, Bohlen P. Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggest its identity with macrophage growth factor. Biochem Biophys Res Commun 1985; 126: 358–64PubMedCrossRefGoogle Scholar
  29. 29.
    Eierman DF, Johnson CE, Haskill JS. Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. J Immunol 1989; 142: 1970–6PubMedGoogle Scholar
  30. 30.
    Roberts AB, Sporn MB. Transforming growth factor-(beta). In: Clark RAF, editor. The molecular and cellular biology of wound repair. 2nd ed. New York (NY): Plenum Press, 1996: 275–308Google Scholar
  31. 31.
    Gray AJ, Bishop JE, Reeves JT, et al. A (alpha) and B (beta) chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci 1993; 104: 409–13PubMedGoogle Scholar
  32. 32.
    Xu J, Clark RAF. Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol 1996; 132: 239–49PubMedCrossRefGoogle Scholar
  33. 33.
    Clark RAF. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J Invest Dermatol 1990; 94 (6 Suppl.): 128S–34SPubMedCrossRefGoogle Scholar
  34. 34.
    Larjava H, Salo T, Haapasalmi K, et al. Expression of integrins and basement membrane components by wound keratinoctyes. J Clin Invest 1993; 92: 1425–35PubMedCrossRefGoogle Scholar
  35. 35.
    Clark RAF, Ashcroft GS, Spencer M-J, et al. Re-epithelialization of normal human excisional wounds is associated with a switch from (alpha) v (beta) 5 to (alpha) v (beta) 6 integrins. Br J Dermatol 1996; 135: 46–51PubMedCrossRefGoogle Scholar
  36. 36.
    Mignatti P, Rifkin DB, Welgus HG, et al. Proteinases and tissue remodelling. In: Clark RAF, editor. The molecular and cellular biology of wound repair. 2nd ed. New York (NY): Plenum Press, 1996: 427–74Google Scholar
  37. 37.
    Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445–52PubMedGoogle Scholar
  38. 38.
    Kanzler MH, Gorsulowsky DC, Swanson NA. Basic mechanisms in the healing cutaneous wound. J Dermatol Surg Oncol 1986; 12: 1156–64PubMedGoogle Scholar
  39. 39.
    Kirsner RS, Eaglstein WH. The wound healing process. Dermatol Clin 1993; 11: 629–40PubMedGoogle Scholar
  40. 40.
    Dawson RA, Goberdhan NJ, Freedlander E, et al. Influence of extracellular matrix proteins on human keratinocyte attachment, proliferation and transfer to a dermal wound model. Burns 1996; 22: 93–100PubMedCrossRefGoogle Scholar
  41. 41.
    Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor alpha and epidermal growth factor. Cell 1987; 50: 1131–7PubMedCrossRefGoogle Scholar
  42. 42.
    Werner S, Peters KG, Longaker MT, et al. Large induction of keratinocyte growth factor in the dermis during wound healing. Proc Natl Acad Sci 1992; 89: 6896–900PubMedCrossRefGoogle Scholar
  43. 43.
    Higashiyama S, Abraham JA, Miller J, et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936–9PubMedCrossRefGoogle Scholar
  44. 44.
    Meddahi A, Caruelle JP, Gold L, et al. New concepts in tissue repair: skin as an example. Diabetes Metab 1996; 22: 274–8PubMedGoogle Scholar
  45. 45.
    Antoniades HN, Galanopuulos T, Neville-Golden J, et al. Injury induces in vivo expression of PDGF and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts. Proc Natl Acad Sci USA 1991; 88: 565–9PubMedCrossRefGoogle Scholar
  46. 46.
    Krane JF, Murphy DP, Carter DM, et al. Synergistic effects of epidermal growth factor and insulin-like growth factor 1/somatemedin C on keratinocyte proliferation may be medicated by IGF 1 transmodulation of the EGF receptor. J Invest Dermatol 1991; 96: 419–24PubMedCrossRefGoogle Scholar
  47. 47.
    Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367–71PubMedCrossRefGoogle Scholar
  48. 48.
    Chvapil M, Koopman CF. Scar formation: physiology and pathological states. Otolaryngol Clin North Am 1984; 17: 265–72PubMedGoogle Scholar
  49. 49.
    Levenson SM, Geever EF, Crowley LV, et al. The healing of rat skin wounds. Ann Surg 1965; 161: 293–308PubMedCrossRefGoogle Scholar
  50. 50.
    Levenson SM. Some challenging wound healing problems for clinicians and basic scientists. In: Dunphy JE, Van Winkle Jr W, editors. Repair and regeneration: the scientific basis for surgical practice. New York (NY): McGraw-Hill, 1969: 309–37Google Scholar
  51. 51.
    Mendoza Jr CB, Postlethwait RW, Johnson WD. Incidence of wound disruption following operation. Arch Surg 1970; 101: 396–8PubMedCrossRefGoogle Scholar
  52. 52.
    Sandblom PH, Peterson P, Muren A. Determination of the tensile strength of the healing wound as a clinical test. Acta Chirurg Scand 1953; 105: 252–7Google Scholar
  53. 53.
    Horan MA, Ashcroft GS. Ageing, defence mechanisms and the immune system. Age Aging 1997; 26: 15S–19SCrossRefGoogle Scholar
  54. 54.
    Lindstedt E, Sandblom P. Wound healing in man: tensile strength of healing wounds in some patient groups. Ann Surg 1975; 181: 842–6PubMedCrossRefGoogle Scholar
  55. 55.
    Goodson WH III, Hunt TK. Development of a new miniature method for the study of wound healing in human subjects. J Surg Res 1982; 33: 394–401PubMedCrossRefGoogle Scholar
  56. 56.
    Jorgensen LN, Kallehave F, Karlsmark T, et al. Reduced collagen accumulation after major surgery. Br J Surg 1996; 83: 1591–4PubMedCrossRefGoogle Scholar
  57. 57.
    Haydock DA, Hill GL. Impaired wound healing in surgical patients with varying degrees of malnutrition. JPEN J Parenter Enteral Nutr 1986; 10: 550–4PubMedCrossRefGoogle Scholar
  58. 58.
    Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321: 76–9PubMedCrossRefGoogle Scholar
  59. 59.
    Stanulis-Praeger BM. Gilchrest BA. Growth factor responsiveness declines during adulthood for human skin-derived cells. Mech Ageing Devel 1986; 35: 185–98CrossRefGoogle Scholar
  60. 60.
    Phillips T, Gilchrist BA. Cultured allogenic keratinocyte grafts in the management of wound healing: prognostic factors. J Dermatol Surg Oncol 1989; 15: 1169–76PubMedGoogle Scholar
  61. 61.
    Compton C, Tong Y, Trockman N, et al. Transforming growth factor and gene expression in cultured human keratinocytes is unaffected by cellular ageing. Arch Dermatol 1995; 131: 683–90PubMedCrossRefGoogle Scholar
  62. 62.
    Reed MJ, Vernon RB, Abrass IB, et al. TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cellular Physiol 1994; 158: 169–79CrossRefGoogle Scholar
  63. 63.
    Kono T, Tanii T, Furukawa M, et al. Correlation between ageing and collagen gel contractility of human fibroblasts. Acta Derm Venereol (Stockh) 1990; 70: 241–4Google Scholar
  64. 64.
    Ashcroft GS, Horan MA, Ferguson MW. The effects of ageing on cutaneous wound healing in mammals. J Anat 1995; 187(Pt 1): 1–26PubMedGoogle Scholar
  65. 65.
    Freedland M, Karmiol S, Rodriguez J, et al. Fibroblast responses to cytokines are maintained during aging. Ann Plast Surg 1995; 35: 290–6PubMedCrossRefGoogle Scholar
  66. 66.
    Ashcroft GS, Horan MA, Ferguson MW. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab Invest 1998; 78: 47–58PubMedGoogle Scholar
  67. 67.
    Ashcroft GS, Horan MA, Herrick SE, et al. Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans. Cell Tissue Res 1997; 290: 581–91PubMedCrossRefGoogle Scholar
  68. 68.
    Ashcroft GS, Herrick SE, Tarnuzzer RW, et al. Human ageing impairs injury-induced in vivo expression of tissue inhibitor of matrix metalloproteinases (TIMP)-1 and -2 proteins and mRNA. J Pathol 1997; 183: 169–76PubMedCrossRefGoogle Scholar
  69. 69.
    Matsuyama N, Takano K, Mashiko T, et al. The possibility of acute inflammatory reaction affects the development ulcers in bedridden elerly patients. Rinsho Byori. 1999; 47: 1039–145PubMedGoogle Scholar
  70. 70.
    Segal JL, Gonzales E, Yousefi S, et al. Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. Arch Phys Med Rehabilitation 1997; 78: 44–7CrossRefGoogle Scholar
  71. 71.
    Bonnefoy M, Coulon L, Bienvenu J, et al. Implication of cytokines in the aggravation of malnutrition and hypercatabolism in elderly patients with severe pressure sores. Age Ageing 1995; 24: 37–42PubMedCrossRefGoogle Scholar
  72. 72.
    Barone EJ, Yager DR, Pozez AL, et al. Interleukin-1α and collagenase activity are elevated in chronic wounds. Plast Reconstr Surg 1998; 102: 1023–7PubMedCrossRefGoogle Scholar
  73. 73.
    Liso Z, Tu JH, Small CB, et al. Increased urine IL-1 levels in aging. Gerontology 1993; 39: 19–27CrossRefGoogle Scholar
  74. 74.
    Cederholm T, Whetline B, Hollstrom K, et al. Enhanced generation of interleukin 1 β and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr 1997; 65: 876–82PubMedGoogle Scholar
  75. 75.
    Noguchi Y, Yoshikawa T, Matsumoto A, et al. Are cytokines possible mediators of cancer cachexia? Surg Today 1996; 26: 467–75PubMedCrossRefGoogle Scholar
  76. 76.
    Keiler U. Pathophysiology of cancer cachexia. Support Care Cancer 1993; 1: 290–4CrossRefGoogle Scholar
  77. 77.
    Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999; 7: 141–7PubMedCrossRefGoogle Scholar
  78. 78.
    Mustoe TA, Cutler NR, Allman RM, et al. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129: 213–9PubMedCrossRefGoogle Scholar
  79. 79.
    Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores. Ann Surg 1992; 216: 401–8PubMedCrossRefGoogle Scholar
  80. 80.
    Robson MC, Abdulla A, Burns BF, et al. Safety and effect of topical recombinant human interleukin-1-β in the management of pressure sores. Wound Repair Regen 1994; 2: 177–81PubMedCrossRefGoogle Scholar
  81. 81.
    Robson MC, Hill DP, Smith PD, et al. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 2000; 231: 600–11PubMedCrossRefGoogle Scholar
  82. 82.
    Robson MC, Phillips LG, Thomason A, et al. Recombinant human derived growth factor: BB for the treatment of chronic pressure ulcers. Ann Plast Surg 1992; 29: 193–201PubMedCrossRefGoogle Scholar
  83. 83.
    Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339: 23–5PubMedCrossRefGoogle Scholar
  84. 84.
    Pierce GF, Tarpley JE, Allman RM, et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 1994; 145: 1399–410PubMedGoogle Scholar
  85. 85.
    d’Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethylcellulose aqueous-based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998; 10: 69–75Google Scholar
  86. 86.
    Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995;21: 71–81PubMedCrossRefGoogle Scholar
  87. 87.
    Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB in patients with chronic neuropathic diabetic ulcers: a phase III, randomized, placebo-controlled, double-blind study. Diabetes Care 1998; 21: 822–7PubMedCrossRefGoogle Scholar
  88. 88.
    Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg 1998: 176 (2A Suppl.): 74–9SCrossRefGoogle Scholar
  89. 89.
    Smiell JM, Wieman J, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335–46PubMedCrossRefGoogle Scholar
  90. 90.
    Richard J-L, Purer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care 1995; 18: 64–9PubMedCrossRefGoogle Scholar
  91. 91.
    Holloway GA, Steed DL, DeMarco MJ, et al. A randomized, controlled, multicenter, dose response trial of activated platelet supernatent, topical CT-102 in chronic, nonhealing, diabetic wounds. Wounds 1993; 5: 198–206Google Scholar
  92. 92.
    Olivencia JA. Pathophysiology of venous ulcers. Dermatol Surg 1999; 25: 880–5PubMedCrossRefGoogle Scholar
  93. 93.
    Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604–6PubMedGoogle Scholar
  94. 94.
    Robson MC, Phillips LG, Cooper DM, et al. The safety and effect of transforming growth factor-β2 for the treatment of venous stasis ulcers. Wound Repair Regen 1995; 3: 157–67PubMedCrossRefGoogle Scholar
  95. 95.
    Poskitt K, James A, Lloyd-Davis E et al. Pinch skin grafting or porcine dermis in venous ulcers: a randomized clinical trial. BMJ 1987; 294: 674–6PubMedCrossRefGoogle Scholar
  96. 96.
    Warburg F, Danielsen L, Madsen S, et al. Vein surgery with or without skin grafting versus conservative treatment for leg ulcers. Acta Derm Venereol (Stockh) 1994; 74(4): 307–9Google Scholar
  97. 97.
    Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998; 134: 293–300PubMedCrossRefGoogle Scholar
  98. 98.
    Mol M, Nanninga B, Eendenburg J, et al. Grafting of venous leg ulcers. J Am Acad Dermatol 1991; 24(1): 77–82PubMedCrossRefGoogle Scholar
  99. 99.
    Lindgren C, Marcusson J, Toftgard R. Treatment of venous leg ulcers with cryopreserved cultured allogeneic keratinocytes: a prospective open controlled study. Br J Dermatol 1998; 139: 271–5PubMedCrossRefGoogle Scholar
  100. 100.
    Teepe R, Roseeuw D, Hermans J, et al. Randomized trial comparing cryopreserved cultured epidermal allografts with hydrocolloid dressings in healing chronic venous ulcers. J Am Acad Dermatol 1993; 29(6): 982–8PubMedCrossRefGoogle Scholar
  101. 101.
    Cullum N, Fletcher A, Semlyen A, et al. Compression therapy for venous leg ulcers. Qual Health Care 1997; 6: 226–31PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Division of Geriatric MedicineSt Louis University Health Science CenterSt LouisUSA

Personalised recommendations